Chronos Therapeutics has appointed Dr Fraser Murray and Dr Timothy Schulz-Utermoehl (pictured) as Vice Presidents of Pre-Clinical Development.

Fraser and Timothy join Chronos from Polleo Pharma, a UK biotech start-up company they co-founded. Both have substantial scientific management expertise acquired in large pharmaceutical companies and previously held senior positions at Shire, AstraZeneca and Merck. Fraser was Senior Director and Head of Discovery Biology for Shire Speciality Pharmaceuticals, focused on CNS and GI disorders, and Tomothy was a Director within the Exploratory Projects Department for Shire Speciality Pharmaceuticals in the UK.

They will be responsible for three pre-clinical research programmes recently acquired by Chronos. These include a dopamine active transporter inhibitor programme in MS fatigue and the Company's orexin 1 antagonist programme in addictive behaviours. A third, undisclosed programme has potential in post-traumatic stress disorder (PTSD).